Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRE | P78334 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24753485 | 0.85 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CTSKCHRNB2 | |
| SCHEMBL16941095 | 0.85 | CTSK (0.39) | HDAC6HDAC1HDAC2CTSKCHRNB2 | |
| SCHEMBL3711368 | 0.84 | CTSK (0.38) | HDAC6HDAC1HDAC2CTSKCHRNB2 | |
| SCHEMBL21258550 | 0.83 | CTSK (0.37) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19709285 | 0.83 | CTSK (0.36) | HDAC6HDAC1HDAC2CTSKCHRNB2 | |
| SCHEMBL21610069 | 0.82 | CTSK (0.38) | HDAC6HDAC1HDAC2CTSKCHRNB2 | |
| SCHEMBL25113381 | 0.82 | CTSK (0.38) | HDAC6HDAC1HDAC2CTSKCHRNB2 | |
| SCHEMBL3708518 | 0.82 | CTSK (0.38) | HDAC6HDAC1HDAC2CTSKCHRNB2 | |
| SCHEMBL18431705 | 0.82 | CTSK (0.38) | HDAC6HDAC1HDAC2CTSKCHRNB2 | |
| SCHEMBL14547678 | 0.82 | CTSK (0.38) | HDAC6HDAC1HDAC2CTSKCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145913-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024020522-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230295149-A1 | MONOBACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150996-A1 | B-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230029557-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-02-02 | — | — | US | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-9556165-B2 | Amidine substituted β-lactam compounds, their preparation and use as antibacterial agents | AICURIS GMBH & CO. KG (DE) | 2017-01-31 | — | — | US | disclosed |
| US-8957082-B2 | Tetrahydropyrrolopyrimidinediones and their use in therapy | CHIESI FARMACEUTICI S.P.A (IT) | 2015-02-17 | — | — | US | disclosed |
| US-20120202826-A1 | Tetrahydropyrrolopyrimidinediones And Their Use In Therapy | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-08-09 | — | — | US | disclosed |
| US-8198288-B2 | Tetrahydropyrrolopyrimidinediones and their use in therapy | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| EP-2024367-B1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | PULMAGEN THERAPEUTICS INFLAMMA (GB) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010009207-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090093477-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| EP-2024367-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Argenta Discovery Limited (GB) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007129060-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007030080-A1 | HETEROCYCLIC COMPOUNDS | S*BIO PTE LTD (SG) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150996-A1 | B-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | LBR, MRPL21, MRPL19 | HDAC6 1320/4885HDAC1 1066/4885HDAC2 2650/4885 |
| US-20230029557-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | ACP1, PTPRCAP, PTPRO | HDAC6 1809/4885HDAC1 790/4885HDAC2 2469/4885 |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | HDAC6 948/4885HDAC1 551/4885HDAC2 1636/4885 |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | ACP1, PTPRCAP, PTPRO | HDAC6 1809/4885HDAC1 790/4885HDAC2 2469/4885 |
| US-20120202826-A1 | Tetrahydropyrrolopyrimidinediones And Their Use In Therapy | SERPINB1, ELANE, MPO | HDAC6 396/4885HDAC1 457/4885HDAC2 963/4885 |
| US-12145913-B2 | Inhibition of Olig2 activity | POU2F2, POU2F1, PLP2 | HDAC6 632/4885HDAC1 517/4885HDAC2 478/4885 |
| US-20090093477-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY | NOX1, NOX3, ELANE | HDAC6 2195/4885HDAC1 1055/4885HDAC2 2464/4885 |
| US-20230295149-A1 | MONOBACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | MRPL21, MRPL19, MRPL12 | HDAC6 3872/4885HDAC1 1077/4885HDAC2 3960/4885 |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | BTK, SYK, LCK | HDAC6 347/4885HDAC1 965/4885HDAC2 756/4885 |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | HDAC6 3025/4885HDAC1 2049/4885HDAC2 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.